Desert Forest

Desert Forest is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of next-generation metabolic therapies. The company focuses on multi-target incretin analogs, particularly triple agonists targeting the GLP-1, GIP, and glucagon receptors. Its lead candidate, DNS-101, is currently in Phase 1 clinical trials for the treatment of obesity and type 2 diabetes. Desert Forest utilizes a proprietary peptide engineering platform to optimize the potency and pharmacokinetic properties of its therapeutic candidates. The firm has attracted significant investment from top-tier venture capital firms like Sequoia China and Gaorong Capital. By targeting multiple metabolic pathways simultaneously, the company aims to achieve superior weight loss and metabolic health outcomes compared to existing mono- or dual-agonists.